WO2003035640A1 - Composes de pyrimidone et compositions pharmaceutiques contenant lesdits composes - Google Patents

Composes de pyrimidone et compositions pharmaceutiques contenant lesdits composes Download PDF

Info

Publication number: WO2003035640A1
Authority: WO; WIPO (PCT)
Prior art keywords: heterocyclic group; group; membered; aromatic hydrocarbon; same
Prior art date: 2001-10-22

Application number

PCT/JP2002/010953

Other languages

English (en)

French (fr)

Inventor

Hitoshi Harada

Osamu Asano

Masato Ueda

Shuhei Miyazawa

Yoshihiko Kotake

Yasuhiro Kabasawa

Masahiro Yasuda

Nobuyuki Yasuda

Original Assignee

Eisai Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-22

Filing date

2002-10-22

Publication date

2003-05-01

2002-10-22 Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.

2002-10-22 Priority to US10/492,547 priority Critical patent/US7160892B2/en

2002-10-22 Priority to EP02802051A priority patent/EP1439176B1/en

2002-10-22 Priority to DE60219051T priority patent/DE60219051T2/de

2002-10-22 Priority to JP2003538156A priority patent/JPWO2003035640A1/ja

2003-05-01 Publication of WO2003035640A1 publication Critical patent/WO2003035640A1/ja

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PCT/JP2002/010953 2001-10-22 2002-10-22 Composes de pyrimidone et compositions pharmaceutiques contenant lesdits composes WO2003035640A1 (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
US10/492,547 US7160892B2 (en)	2001-10-22	2002-10-22	Pyrimidone compounds and pharmaceutical compositions containing the same
EP02802051A EP1439176B1 (en)	2001-10-22	2002-10-22	Pyrimidone compounds and pharmaceutical compositions containing the same
DE60219051T DE60219051T2 (de)	2001-10-22	2002-10-22	Pyrimidonverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
JP2003538156A JPWO2003035640A1 (ja)	2001-10-22	2002-10-22	ピリミドン化合物及びその医薬組成物

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001/324142		2001-10-22
JP2001324142		2001-10-22

Publications (1)

Publication Number	Publication Date
WO2003035640A1 true WO2003035640A1 (fr)	2003-05-01

Family

ID=19140918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/010953 WO2003035640A1 (fr)	2001-10-22	2002-10-22	Composes de pyrimidone et compositions pharmaceutiques contenant lesdits composes

Country Status (6)

Country	Link
US (1)	US7160892B2 (ja)
EP (1)	EP1439176B1 (ja)
JP (1)	JPWO2003035640A1 (ja)
DE (1)	DE60219051T2 (ja)
TW (1)	TWI301834B (ja)
WO (1)	WO2003035640A1 (ja)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005060401A (ja) *	2003-08-13	2005-03-10	Syrrx Inc	ジペプチジルペプチダーゼ阻害剤
JP2007505121A (ja) *	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
EP1732541A4 (en) *	2004-04-07	2008-03-05	Takeda Pharmaceutical	CYCLIC COMPOUNDS
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7781584B2 (en)	2004-03-15	2010-08-24	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US8084605B2 (en)	2006-11-29	2011-12-27	Kelly Ron C	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8222411B2 (en)	2005-09-16	2012-07-17	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP2013518864A (ja) *	2010-02-05	2013-05-23	ヘプタレスセラピューティックスリミテッド	１，２，４−トリアジン−４−アミン含有誘導体
WO2013138352A1 (en)	2012-03-15	2013-09-19	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
US8906901B2 (en)	2005-09-14	2014-12-09	Takeda Pharmaceutical Company Limited	Administration of dipeptidyl peptidase inhibitors
WO2014197720A2 (en)	2013-06-05	2014-12-11	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2017146129A1 (ja) *	2016-02-24	2017-08-31	株式会社Ｌｔｔバイオファーマ	過敏性腸症候群治療剤
WO2020135210A1 (zh) *	2018-12-28	2020-07-02	四川科伦博泰生物医药股份有限公司	取代芳基化合物及其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI330183B (ja) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
CN103012254A (zh)	2005-05-10	2013-04-03	英特芒尼公司	用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
US20080009623A1 (en) *	2006-07-06	2008-01-10	Eisai R&D Management Co., Ltd.	Pyrimidine compounds
EP2296653B1 (en)	2008-06-03	2016-01-27	Intermune, Inc.	Compounds and methods for treating inflammatory and fibrotic disorders
WO2010009194A1 (en) *	2008-07-16	2010-01-21	King Pharmaceuticals Research And Development, Inc.	Methods of treating atherosclerosis
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
US9753042B2 (en) *	2013-04-23	2017-09-05	Rosalind Franklin University Of Medicine And Science	Kits for determining male fertility by measuring levels of a2V-ATPase, G-CSF, MIP 1 alpha, MCP-1, and methods and kits for improving reproductive outcomes in artificial insemination procedures
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
WO2020014332A1 (en) *	2018-07-10	2020-01-16	Nikang Therapeutics, Inc.	Adenosine receptor binding compounds
CN111377873B (zh) *	2018-12-28	2023-03-28	四川科伦博泰生物医药股份有限公司	氨基嘧啶化合物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024782A2 (en) *	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidine compounds and their use
WO1998024780A2 (en) *	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidinone and pyridinone compounds and their use
WO1999035147A1 (fr) *	1998-01-05	1999-07-15	Eisai Co., Ltd.	Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete
US6096753A (en) *	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4725600A (en) *	1984-07-13	1988-02-16	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
US4673680A (en)	1985-09-18	1987-06-16	Pendleton Robert G	α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
JPH06102662B2 (ja)	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
JPH04271770A (ja)	1991-02-27	1992-09-28	Asahi:Kk	お茶
CN1088053A (zh)	1993-01-04	1994-06-22	谷中村	一种益寿保健茶叶
JPH06211669A (ja)	1993-01-14	1994-08-02	Kyowa Hakko Kogyo Co Ltd	腸運動の異常亢進治療剤
WO1994016702A1 (en)	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Remedy for irregular bowel movement
US6096748A (en)	1996-03-13	2000-08-01	Smithkline Beecham Corporation	Pyrimidine compounds useful in treating cytokine mediated diseases
JP3990061B2 (ja)	1998-01-05	2007-10-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
AU763658B2 (en)	1998-06-02	2003-07-31	Osi Pharmaceuticals, Inc.	Pyrrolo(2,3d)pyrimidine compositions and their use
AU4506399A (en)	1998-06-05	1999-12-30	Novartis Ag	Aryl pyridinyl thiazoles
AR023052A1 (es)	1998-09-25	2002-09-04	Mitsuharu Yoshimura Milton	Derivados de pirimidona
AUPP672198A0 (en)	1998-10-23	1998-11-19	Fujisawa Pharmaceutical Co., Ltd.	Pyrazolopyridine compound and pharmaceutical use thereof
AU778450B2 (en)	1999-07-02	2004-12-09	Eisai R&D Management Co., Ltd.	Fused imidazole compounds and remedies for diabetes mellitus
EP1136486A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
EP1136482A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
AU2001248365A1 (en) *	2000-03-23	2001-10-03	Mitsubishi Pharma Corporation	2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
AU2001252606B2 (en)	2000-04-26	2005-07-07	Eisai R&D Management Co., Ltd.	Medicinal compositions promoting bowel movement

2002
- 2002-10-21 TW TW091124228A patent/TWI301834B/zh active
- 2002-10-22 EP EP02802051A patent/EP1439176B1/en not_active Expired - Lifetime
- 2002-10-22 JP JP2003538156A patent/JPWO2003035640A1/ja active Pending
- 2002-10-22 DE DE60219051T patent/DE60219051T2/de not_active Expired - Lifetime
- 2002-10-22 WO PCT/JP2002/010953 patent/WO2003035640A1/ja active IP Right Grant
- 2002-10-22 US US10/492,547 patent/US7160892B2/en not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024782A2 (en) *	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidine compounds and their use
WO1998024780A2 (en) *	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidinone and pyridinone compounds and their use
US6096753A (en) *	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
WO1999035147A1 (fr) *	1998-01-05	1999-07-15	Eisai Co., Ltd.	Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 77, Columbus, Ohio, US; abstract no. 34471J, XP002961047 *
DISS. PHARM. PHARMACOL., vol. 24, no. 1, 1972, pages 27 - 37 *
HANNAH ET AL., BIOORG. MED. CHEM., vol. 8, no. 4, 2000, pages 739 - 750, XP002961046 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7687625B2 (en)	2003-03-25	2010-03-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7790736B2 (en)	2003-08-13	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2005060401A (ja) *	2003-08-13	2005-03-10	Syrrx Inc	ジペプチジルペプチダーゼ阻害剤
US7579357B2 (en)	2003-08-13	2009-08-25	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7723344B2 (en)	2003-08-13	2010-05-25	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7470700B2 (en)	2003-08-13	2008-12-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7790734B2 (en)	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007505121A (ja) *	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
US7807689B2 (en)	2004-03-15	2010-10-05	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8188275B2 (en)	2004-03-15	2012-05-29	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7781584B2 (en)	2004-03-15	2010-08-24	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7906523B2 (en)	2004-03-15	2011-03-15	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8329900B2 (en)	2004-03-15	2012-12-11	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8288539B2 (en)	2004-03-15	2012-10-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8173663B2 (en)	2004-03-15	2012-05-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7897607B2 (en)	2004-04-07	2011-03-01	Takeda Pharmaceutical Company Limited	Cyclic compounds
EP1732541A4 (en) *	2004-04-07	2008-03-05	Takeda Pharmaceutical	CYCLIC COMPOUNDS
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8906901B2 (en)	2005-09-14	2014-12-09	Takeda Pharmaceutical Company Limited	Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en)	2005-09-16	2012-07-17	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en)	2006-11-29	2011-12-27	Kelly Ron C	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP2013518864A (ja) *	2010-02-05	2013-05-23	ヘプタレスセラピューティックスリミテッド	１，２，４−トリアジン−４−アミン含有誘導体
KR20180028550A (ko) *	2010-02-05	2018-03-16	헵테얼즈 테라퓨틱스 리미티드	1,2,4-트리아진-4-아민 유도체들
KR101993867B1 (ko)	2010-02-05	2019-06-27	헵테얼즈 테라퓨틱스 리미티드	1,2,4-트리아진-4-아민 유도체들
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013138352A1 (en)	2012-03-15	2013-09-19	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en)	2012-03-15	2020-09-16	Bausch Health Ireland Limited	Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en)	2012-03-15	2024-01-24	Bausch Health Ireland Limited	Formulations of guanylate cyclase c agonists and methods of use
WO2014197720A2 (en)	2013-06-05	2014-12-11	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2017146129A1 (ja) *	2016-02-24	2017-08-31	株式会社Ｌｔｔバイオファーマ	過敏性腸症候群治療剤
WO2020135210A1 (zh) *	2018-12-28	2020-07-02	四川科伦博泰生物医药股份有限公司	取代芳基化合物及其制备方法和用途

Also Published As

Publication number	Publication date
EP1439176B1 (en)	2007-03-21
DE60219051T2 (de)	2007-11-22
US7160892B2 (en)	2007-01-09
JPWO2003035640A1 (ja)	2005-02-10
TWI301834B (en)	2008-10-11
EP1439176A1 (en)	2004-07-21
US20040259865A1 (en)	2004-12-23
DE60219051D1 (de)	2007-05-03
EP1439176A4 (en)	2005-02-09

Publication	Publication Date	Title
WO2003035640A1 (fr)	2003-05-01	Composes de pyrimidone et compositions pharmaceutiques contenant lesdits composes
WO2003035639A1 (fr)	2003-05-01	Compose de pyrimidine et composition medicinale contenant ledit compose
AU7774101A (en)	2002-02-25	2-aminopyridine compounds and use thereof as drugs
NO20070532L (no)	2007-01-29	Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
WO2007090141A3 (en)	2007-11-15	Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
SG151249A1 (en)	2009-04-30	6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2006015357A3 (en)	2006-10-26	2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0206860D0 (en)	2002-05-01	Compounds
EP1382603A4 (en)	2004-12-29	NITROGEN COMPOUND WITH CONDENSED RINGS HAVING A PYRAZOLYL GROUP AND AS A SUBSTITUTE, AND MEDICAL COMPOSITION COMPRISING SAME
WO2006084017A3 (en)	2006-12-14	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
NO331068B1 (no)	2011-09-26	Benzazepinderivater for behandling av nevrologiske forstyrrelser.
WO2005058843A8 (en)	2006-06-15	Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2506441A1 (en)	2004-06-24	5-substituted-pyrazine or pyridine glucokinase activators
NO20070526L (no)	2007-01-29	Kinazolindionderivater som parp-inhibitorer
TWI262915B (en)	2006-10-01	Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
BR9809451A (pt)	2000-06-20	Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
AU1099302A (en)	2002-05-15	Medicinal compositions for concominant use as anticancer atent
MY137522A (en)	2009-02-27	Novel anti-inflammatory androstane derivatives.
NO20062892L (no)	2006-08-09	7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
WO2006069363A3 (en)	2007-05-10	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2002048115A3 (en)	2002-09-06	Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests
WO2003095455A3 (en)	2003-12-24	Substituted pyrazolopyrimidines
CA2337825A1 (en)	2000-02-17	Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
NO20063230L (no)	2006-09-12	CRF receptorantagonister og fremgangsmater for fremstilling derav
WO2003059903A3 (de)	2003-12-11	Substituierte 4-aminopyridin-derivate als schädlingsbekämpfungsmittel

Legal Events

Date	Code	Title	Description
2003-05-01	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
2003-05-01	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-05-30	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-06-25	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-04-05	WWE	Wipo information: entry into national phase	Ref document number: 2003538156 Country of ref document: JP
2004-04-14	WWE	Wipo information: entry into national phase	Ref document number: 10492547 Country of ref document: US
2004-04-19	WWE	Wipo information: entry into national phase	Ref document number: 2002802051 Country of ref document: EP
2004-07-21	WWP	Wipo information: published in national office	Ref document number: 2002802051 Country of ref document: EP
2007-03-21	WWG	Wipo information: grant in national office	Ref document number: 2002802051 Country of ref document: EP